The bridge is already built: management walks investors from today's numbers to a bigger business using only pieces alre
The model's full reasoning — Q3 2018 call → NOWe need answer only YES/NO. Need analyze transcript. Need determine if management's forward story over next year built primarily out of specific pieces already secured/in motion, not hopes/pipeline/general demand. Need identify named components, near-dated, material. Let's parse. Company Agios. Q3 2018. Key updates: TIBSOVO launch, IDHIFA. Forward: sNDA for TIBSOVO in newly diagnosed AML not eligible standard therapies by end Jan 2019. FDA accepted Real-Time Oncology Review. Phase 3 AGILE revised EFS endpoint, enrollment completion 2020 (a year earlier). HOVON 150 Phase 3 initiate this quarter. MAA for ivosidenib relapsed/refractory AML by end 2018. CLARITY cholangiocarcinoma enrollment complete first-half 2019. Glioma decision by year-end. AG-270 dose escalation. AG-636 IND submitted. Mitapivat PK deficiency pivotal trials enrollment complete 2019. Thalassemia Phase 2 start by end year. TIBSOVO launch revenue $4.5M first partial quarter. Launch progress. Question: On this call, when management explains where business is heading over roughly NEXT YEAR, does it build explanation primarily out of SPECIFIC PIECES ALREADY SECURED/IN MOTION rather than market hopes/pipeline/general demand? Need answer YES if management's own words convey path from today's reported numbers to meaningfully larger/stronger near-term business as walk across pieces that already exist. Need consider if forward story includes regulatory submissions, trial initiations, enrollment completions. Are these "pieces already secured/in motion"? They are clinical development milestones, not necessarily revenue. But business includes pipeline. Need assess. The question likely from a framework about "backlog" or "secured business" vs pipeline. Here management discusses regulatory submissions, clinical trials, launch. Are these "specific pieces already secured"? sNDA submission planned, not approved. FDA accepted RTOR. That is a regulatory process, not a committed contract. But it is in motion. However, the forward story is mostly about clinical development milestones, not necessarily revenue growth. The company's business is biotech; near-term value from regulatory approvals and trial data. But the question asks "business the company has already locked in" - results understate business already locked in. Management mentions TIBSOVO launch, sNDA submission, MAA submission, trial enrollment.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ERO | Ero Copper Corp. | Q1 2024 | 2024-05-10 | A |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| GOLD | Barrick Gold Corporation | Q3 2023 | 2023-11-02 | C |
| TGLS | Tecnoglass Inc. | Q2 2023 | 2023-08-08 | A |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| OEC | Orion Engineered Carbons S.A. | Q4 2022 | 2023-02-17 | B+ |
| ESEA | Euroseas Ltd. | Q4 2022 | 2023-02-15 | C+ |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| PKOH | Park-Ohio Holdings Corp. | Q3 2022 | 2022-11-13 | B |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| MEC | Mayville Engineering Company, Inc. | Q3 2022 | 2022-11-05 | B+ |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| ZVIA | Zevia PBC | Q1 2022 | 2022-05-12 | B |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| ADSE | ADS-TEC Energy PLC | Q4 2021 | 2022-04-28 | D |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| RNW | ReNew Energy Global Plc | Q2 2022 | 2021-11-18 | C |
| EGY | VAALCO Energy, Inc. | Q2 2021 | 2021-08-12 | B |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| KNDI | Kandi Technologies Group, Inc. | Q2 2021 | 2021-08-09 | F |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| WES | Western Midstream Partners, LP | Q3 2018 | 2018-10-31 | D |
| KOP | Koppers Holdings Inc. | Q2 2018 | 2018-08-12 | C+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| XOM | Exxon Mobil Corporation | Q2 2018 | 2018-07-27 | C |
| FSS | Federal Signal Corporation | Q1 2018 | 2018-05-12 | A |
| HLX | Helix Energy Solutions Group, Inc. | Q1 2018 | 2018-04-24 | B+ |
| UPLD | Upland Software, Inc. | Q4 2017 | 2018-03-08 | C+ |
| SBSI | Southside Bancshares, Inc. | Q4 2017 | 2018-02-06 | A |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| LEA | Lear Corporation | Q2 2017 | 2017-07-26 | B+ |
| PSX | Phillips 66 | Q4 2016 | 2017-02-03 | C+ |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
| ACCO | ACCO Brands Corporation | Q1 2016 | 2016-04-27 | B+ |
EVGO · Q2 2022 → YESThe question is about whether management's explanation of the next year's business is built primarily from specific pieces already secured or in motion, making current results understate the locked-in...YES The transcript shows management framing the next-year outlook around the newly announced, signed GM-Pilot eXtend deal (up to 2,000 stalls at 500 locations, with EVgo procuring, constructing, operating, and maintaining, delivering both near-term revenue and longer-term contracted cash flows that already exceed IRR hurdles) plus the Delta supply agreement (1,000+ chargers for 2,000 stalls through 2026) and the GSA BPA (which removes procurement friction for federal fleets). These pieces are presented as already committed and in motion, with explicit timing for revenue ramp in H2 2022 and into 202 3, while the company notes it has baked some of the PFJ contribution into its 2022 guidance. The structure treats these secured elements as the primary bridge from today’s numbers to a meaningfully larger business, rather than relying on pipeline, demand, or future bids. Other items (NEVI solicitations, fleet pilots ) are secondary and contingent, but the core forward posture is built on the named, already-executed contracts and programs. Current results visibly understate the locked-in trajectory because the eXtend model shifts cash flows forward and the secured stalls/contracts are only beginning to flow.
BRBR · Q4 2023 → YESThe question is about whether management's explanation of the next year's business is built primarily from specific pieces already secured or in motion, such that current results understate the locked...YES The transcript shows management framing fiscal '24 growth as driven by concrete, already-committed pieces: the two co-man additions from '23 that are scaling, the Michael Foods greenfield facility that starts up in December and will be a "much larger contributor" in the second half of '24, the 20 %+ production growth plan (40 % from new co-mans in '24, 40 % from lapping prior adds, 20 % from existing), and the restart of shake promotions in Q2 plus marketing step-up in Q4 once target weeks of supply are reached. These are presented as nameable, scheduled 2024 actions that will enable double-digit volume growth for both Premier Protein and Dymatize, with the current-year results (22 % sales growth under capacity constraints) treated as a base that the locked-in capacity ramp will visibly outgrow.
MEC · Q3 2022 → YESThe question is about whether management's explanation of the next year's business is built primarily from specific pieces already secured or in motion, such that current results understate the locked...YES The transcript shows management framing 2023 growth primarily around specific, already secured or in-motion pieces: the electric side-by-side family of parts (production fully launching in 2023), the reshoring project for the commercial vehicle customer (production scheduled to start early 2023), the high-value ag takeover project (already awarded), incremental business on the light-duty truck platform, and the new industrial infrastructure customer relationship (quickly supported and expected to grow). These are presented as nameable, committed items whose contributions are beginning or ramping over the coming year.